
[Federal Register Volume 82, Number 50 (Thursday, March 16, 2017)]
[Notices]
[Page 14002]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05247]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-N-2016-4198]


Public Meeting on Patient-Focused Drug Development for 
Sarcopenia; Request for Comments; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Public Meeting on Patient-Focused Drug Development for 
Sarcopenia'' that appeared in the Federal Register of December 14, 2016 
(81 FR 90361). The document announced a public meeting and an 
opportunity for public comment on Patient-Focused Drug Development for 
Sarcopenia. The location of the meeting has changed and this document 
provides the updated meeting location.

FOR FURTHER INFORMATION CONTACT: Meghana Chalasani, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240-
402-6525, FAX: 301-847-8443, Meghana.Chalasani@fda.hhs.gov.
    In the Federal Register of Wednesday, December 14, 2016, in FR Doc. 
2016-29998, the following correction is made:
    1. On page 90361, in the second column, in the first sentence of 
the ADDRESSES section, ``FDA White Oak Campus, 10903 New Hampshire 
Ave., Bldg. 31 Conference Center, the Great Room, (Rm. 1503), Silver 
Spring, MD 20993-0002.'' is corrected to read ``Tommy Douglas 
Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903.''

    Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-05247 Filed 3-15-17; 8:45 am]
 BILLING CODE 4164-01-P


